Aleksandra (Sasha) Gracia, Ph.D. Associate


Speaks:  English

Year of Call: 2016 - Ontario


Primary office:  Ottawa




Aleksandra (Sasha) Gracia, Ph.D.

Dr. Aleksandra Gracia is an associate lawyer in Gowling WLG’s Ottawa office, practising in the Intellectual Property Group. She is a lawyer with a doctorate in immunology and vaccinology.

Aleksandra provides strategic advice to pharmaceutical, life science and biotechnology companies with respect to patent protection, including drafting, prosecution, due diligence and portfolio management.

Aleksandra obtained her B.Sc. degree in Biochemistry & Microbiology from the University of Victoria, and her Ph.D. and J.D. degrees from the University of Saskatchewan. She has extensive technical expertise in biochemistry, microbiology and immunology. During her doctoral studies, she was a member of the Vaccine & Infectious Disease Organization’s (VIDO) – International Vaccine Centre (InterVac) Neonatal Immunization Group. At VIDO, with funding from the Bill & Melinda Gates Foundation, she assisted in the development of a new vaccine adjuvant platform for use in the immunization of infants in developing countries.

Prior to joining Gowling WLG, Aleksandra worked at a Canadian law firm that focused exclusively on IP and tech law.

Career & Recognition

Filter timeline:
  • 2016

    • Qualifications (Year of Call/Admission, etc.)
       2016
      Year of Call, Ontario
  • 2014

    • Education
       2014
      University of Saskatchewan, JD
  • 2012

    • Education
       2012
      University of Saskatchewan, Ph.D., Immunology & Vaccinology
  • 2006

    • Education
       2006
      University of Victoria, B.Sc. Biochemistry & Microbiology

Memberships

Intellectual Properly Institute of Canada (IPIC)

Publications

  • “The Experimental Use Exception under the Recently Amended Canadian Patent Act” (Co-author: David Schwartz), Lexology, June 20, 2019.
  • “Keeping up with technology – goods versus services”, World Trademark Review Daily, April 6, 2016.
  • “Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies” (Co-authors: Monika Polewicz, Srinivas Garlapati, Jill van Kessel, Stacy Strom, Scott A Halperin, Robert E W Hancock, Andrew A Potter, Lorne A Babiuk, Volker Gerdts), Vaccine, June 28, 2013, Volume 31, Issue 31, pp.3148-3155.
  •  “Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets” (Co-authors: Monika Polewicz, Rachelle Buchanan, Stacy Strom, Scott A Halperin, Andrew A Potter, Lorne A Babiuk, Volker Gerdts), Vaccine, October 13, 2011, Volume 29, Issue 44, pp. 7718-26.
  • “Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations” (Co-authors: Monika Polewicz, Scott A Halperin, Robert E W Hancock, Andrew A Potter, Lorne A Babiuk, Volker Gerdts), Vaccine, February 11, 2011, Volume 29, Issue 8, pp. 1595-604.